Piramal Pharma Solutions (PPS), a leading global contract development and manufacturing organisation (CDMO) has announced that its Aurora, Canada drug substance site has received a $1,753,620 investment from the Ontario government through the Life Sciences Scale-Up Fund (LSSUF), enabling PPS to upgrade site infrastructure and commercialise Ontario-made health technologies for new markets.
With support from the government of Ontario, Piramal Pharma is investing US $5.3 million to upgrade site infrastructure at its Aurora facility, strengthening Ontario’s pharmaceutical manufacturing and bolstering domestic production of APIs.
This project will enhance R&D and clinical API production, ensure the commercial availability of critical drug substances, and support a resilient and globally competitive life sciences industry in Ontario.
The investment will create 12 new jobs and protect 183 existing positions.
First launched in 2024, the $24 million LSSUF works in tandem with the government’s health innovation pathway to advance the objectives of phase 2 of Ontario’s Life Sciences Strategy and strengthen Ontario’s position as a global leader in health innovation. Building on the fund’s initial success, the 2026 Ontario Budget invested an additional $24 million to support Ontario companies whose work will accelerate the adoption of innovative technologies in the health-care system and support the province’s broader vision of providing connected, convenient care closer to home.
